Abstract
Objectives Current study aimed to investigate radiomics features derived from two-center diffusion-MRI to differentiate benign and hepatocellular carcinoma (HCC) liver nodules.
Methods A total of 328 patients with 517 LI-RADS 2-5 nodules were included. MR images were retrospectively collected from 3T and 1.5T MRI vendors. Lesions were categorized into 242 benign and 275 HCC based on follow-up imaging for LR-2,3 and pathology results for LR4,5 nodules, and randomly divided into training (80%) and test (20%) sets. Preprocessing included resampling and normalization. Radiomics features were extracted from lesion volume-of-interest (VOI) on diffusion Images. Scanner variability was corrected using ComBat harmonization method followed by High-correlation filter, PCA filter, and LASSO to select important features. Best classifier model was selected by 10-fold cross-validation, and accuracy was assessed on the test dataset.
Results 1,434 features were extracted, and subsequent classifiers were constructed based on the 16 most important selected features. Notably, support-vector machine (SVM) demonstrated better performance in the test dataset in distinguishing between benign and HCC nodules, achieving an accuracy of 0.92, sensitivity of 0.94, and specificity of 0.86.
Conclusions Utilizing diffusion-MRI radiomics, our study highlights the performance of SVM, trained on lesions’ diffusivity characteristics, in distinguishing benign and HCC nodules, ensuring clinical potential. It is suggested that further evaluations be conducted on multi-center datasets to address harmonization challenges.
Advances in knowledge Integration of diffusion radiomics, for monitoring water restriction patterns as tumor histopathological index, with machine learning models demonstrates potential for achieving a reliable noninvasive method to improve the current diagnosis criteria.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the Tehran University of Medical Sciences (grant no. 1398-02-51-43309). The funder had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective study was approved by the institutional review board of the Cancer Institute, Tehran University of Medical Sciences.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
